

Comparative Evaluation of Antimicrobial Susceptibility Patterns in *Klebsiella* spp. and *Proteus* spp. Isolates from Urine Cultures in a Tertiary Care Hospital, Lahore

Warda Waheed¹, Azka Mubeen², Irfan Bashir³, Ehsan Ahmad⁴, Farhan Rasheed⁵, Sidra Iqbal⁶, Ijaz Ahmad⁷

^{1,2,4,6,7} Department of Medical Lab Technology, Faculty of Allied Health Sciences, The Superior University, Lahore, Pakistan

⁵ Ameer-ud-Din Medical College/Postgraduate Medical Institute, Lahore, Pakistan

*Corresponding author: Azka Mubeen, azkamubeen786@gmail.com

Cite this Article Received: 09 March 2026; Accepted: 02 April 2026; Published: 11 May 2026

Author Contributions: Concept: KF; Design: A; Data Collection: HI; Analysis: GH; Drafting: KF, A, GH, HI. **Ethical Approval:** The Superior University, Lahore, Pakistan.

Informed Consent: Written informed consent was obtained from all participants; **Conflict of Interest:** The authors declare no conflict of interest. **Funding:** No external funding; **Data Availability:** Available from the corresponding author on reasonable request; **Acknowledgments:** N/A.

ABSTRACT

Background: Urinary tract infections caused by antimicrobial-resistant Gram-negative organisms are a growing challenge for empirical therapy, particularly in tertiary care settings. Local susceptibility data are essential for guiding antibiotic selection and supporting antimicrobial stewardship. **Objective:** To compare the antimicrobial susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. isolated from urine cultures in a tertiary care hospital in Lahore, Pakistan. **Methods:** This observational, cross-sectional, laboratory-based study was conducted in the Pathology Department of Ameer Ud Din Medical College/Post Graduate Medical Institute, Lahore, from January 2024 to December 2024. A total of 8,745 midstream clean-catch urine specimens were processed using standard microbiological culture methods. Significant bacterial isolates were identified by conventional biochemical testing, and antimicrobial susceptibility testing was performed using the Kirby–Bauer disk diffusion method. Susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. were summarized as frequencies and percentages. **Results:** Of 8,745 urine specimens, 3,326 (38.0%) showed significant bacterial growth. Among culture-positive samples, *Klebsiella* spp. were isolated in 312 (9.4%) cases and *Proteus* spp. in 48 (1.4%) cases. *Proteus* spp. showed complete susceptibility to imipenem and meropenem (100% each), while *Klebsiella* spp. showed lower susceptibility to imipenem (73%) and meropenem (72%). Ceftazidime-avibactam susceptibility was 81% in *Proteus* spp. and 64% in *Klebsiella* spp. Piperacillin/tazobactam susceptibility was higher in *Proteus* spp. (79%) than *Klebsiella* spp. (46%). Fluoroquinolone susceptibility was reduced in both organisms, with ciprofloxacin and levofloxacin susceptibility of 42% in *Klebsiella* spp. and 46% in *Proteus* spp. **Conclusion:** *Proteus* spp. retained high susceptibility to carbapenems, whereas *Klebsiella* spp. showed comparatively reduced susceptibility across several antibiotic classes. The low fluoroquinolone susceptibility in both organisms highlights the need for routine culture-based testing, updated local antibiograms, and susceptibility-guided therapy for urinary tract infections. **Keywords:** Antimicrobial resistance; Urinary tract infection; *Klebsiella* spp.; *Proteus* spp.; Antibiogram; Kirby–Bauer disk diffusion.

INTRODUCTION

Urinary tract infections (UTIs) remain among the most frequently encountered bacterial infections in both community and hospital settings, and their management has become increasingly complicated by the global rise of antimicrobial resistance. Gram-negative uropathogens are of particular concern because they often acquire resistance to commonly used empirical agents, leading to delayed effective therapy, increased healthcare costs, prolonged illness, and greater reliance on broader-spectrum or last-line antibiotics. In tertiary care hospitals, where prior antibiotic exposure, recurrent infections, catheter

use, and comorbidities are frequently encountered, local antimicrobial susceptibility data are essential for guiding rational treatment decisions and supporting antimicrobial stewardship (1,2).

Among Gram-negative organisms causing UTIs, *Klebsiella* spp. and *Proteus* spp. are clinically important because they are associated with complicated infections and variable antimicrobial susceptibility profiles. *Klebsiella* species, particularly in hospital environments, have been increasingly linked with reduced susceptibility to several conventional beta-lactam antibiotics and other commonly used agents. *Proteus* species, especially *Proteus mirabilis*, are also important uropathogens in complicated urinary tract infections, particularly among patients with long-term catheterization, structural or functional urinary tract abnormalities, and renal calculi. Their urease production promotes alkaline urine, crystalline biofilm formation, stone development, catheter encrustation, and bacterial persistence, which makes them clinically relevant in recurrent and catheter-associated infections (3,9–12).

Empirical treatment of UTIs depends heavily on knowledge of local pathogen distribution and antibiotic susceptibility patterns. However, resistance profiles vary substantially between countries, regions, hospitals, and even between organisms isolated from the same clinical specimen type. Fluoroquinolones, cephalosporins, beta-lactam/beta-lactamase inhibitor combinations, aminoglycosides, carbapenems, fosfomycin, nitrofurantoin, and other reported agents may show differing in-vitro activity against *Klebsiella* and *Proteus* isolates. Therefore, organism-specific antibiogram data are necessary for more appropriate clinical decision-making (4,5).

In Pakistan, antimicrobial misuse and empirical prescribing remain important contributors to resistance, making updated local surveillance data from tertiary care laboratories important for clinical practice. Although UTIs are common, comparative local data on susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. from urine cultures remain useful for selecting appropriate empirical therapy and preserving the effectiveness of higher-tier antimicrobial agents. Therefore, this study aimed to compare the antimicrobial susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. isolated from urine cultures processed at a tertiary care hospital in Lahore, Pakistan, and to identify organism-specific susceptibility trends relevant to empirical treatment decisions and local antibiogram development.

MATERIALS AND METHODS

This observational, cross-sectional, laboratory-based study was conducted in the Pathology Department of Ameer Ud Din Medical College/Post Graduate Medical Institute, Lahore, Pakistan, over a one-year period from January 2024 to December 2024. The study included urine specimens submitted for routine microbiological culture and antimicrobial susceptibility testing during the study period. A total of 8,745 midstream clean-catch urine specimens were processed, of which 3,326 showed significant bacterial growth. Among the culture-positive specimens, 312 *Klebsiella* spp. and 48 *Proteus* spp. isolates were included for comparative antimicrobial susceptibility analysis.

Midstream clean-catch urine samples were collected aseptically in sterile, leak-proof containers. Approximately 10–20 mL of urine was obtained from each patient and transported to the laboratory for processing. Samples were processed immediately where possible; when delay was unavoidable, specimens were stored at 4°C for a limited duration before culture. Before inoculation, each urine specimen was mixed thoroughly to ensure homogeneity. For microbiological culture, urine samples were inoculated onto Cysteine-Lactose-Electrolyte-Deficient agar using a calibrated loop and the semi-quantitative streaking technique. Culture plates were incubated aerobically at 37°C for 18–24 hours. Significant bacterial growth was assessed according to routine laboratory criteria, and preliminary identification of bacterial isolates was performed using colony morphology, Gram staining, and catalase testing. Further identification and characterization of isolates were carried out using standard biochemical tests, including oxidase, citrate utilization, urease activity, methyl red, and Triple Sugar Iron tests. Isolates identified as *Klebsiella* spp. and *Proteus* spp. were selected for comparative analysis.

Antimicrobial susceptibility testing was performed using the Kirby–Bauer disk diffusion method on Mueller–Hinton agar. A standardized bacterial inoculum equivalent to 0.5 McFarland turbidity standard was prepared and spread evenly across the agar surface to produce a uniform lawn of growth. After the inoculated plates were allowed to dry for approximately 3–5 minutes, antibiotic disks were applied aseptically at appropriate distances and gently pressed to ensure complete contact with the agar surface. Antibiotic disks were stored at 4°C in sealed containers and brought to room temperature before use to maintain disk potency. Following incubation, inhibition zones were measured and interpreted according to CLSI/EUCAST laboratory guidelines used by the institutional microbiology laboratory. Quality-control procedures were followed during culture and susceptibility testing; where available, standard control strains were used to verify media performance, disk potency, and zone-size interpretation.

The antibiotic panel included agents reported in the laboratory susceptibility records, including aminoglycosides, beta-lactam/beta-lactamase inhibitor combinations, carbapenems, cephalosporins, fluoroquinolones, fosfomycin, nitrofurantoin, tetracycline-class agents, tigecycline, and colistin. However, tigecycline, minocycline, and colistin were interpreted cautiously because these agents are not routinely preferred urinary antimicrobial options and require guideline-based interpretive validity.

The primary study variables were organism type and antimicrobial susceptibility pattern. The main outcome was the proportion of *Klebsiella* spp. and *Proteus* spp. isolates reported as susceptible to each tested antibiotic. Additional descriptive variables included total urine samples processed, culture-positive and culture-negative results, sex distribution of submitted samples, and frequency of the two target organisms among culture-positive samples. Culture positivity was calculated using the total number of urine samples as the denominator, whereas organism frequency was calculated among culture-positive samples.

Data were entered and analyzed using SPSS software. Categorical variables were summarized as frequencies and percentages. Antimicrobial susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. were compared descriptively across antibiotic classes. No inferential statistical testing was retained because the available dataset was summarized as aggregate susceptibility percentages rather than isolate-level susceptibility counts for each antibiotic. Ethical approval for the study was obtained from the relevant institutional ethics committee before data collection. All urine specimens were processed as part of routine diagnostic microbiology services, and patient confidentiality was maintained throughout the study by using anonymized laboratory data. Duplicate isolates, contaminated specimens, and samples with incomplete laboratory records were excluded from the final analysis.

RESULTS

A total of 8,745 urine specimens were processed during the study period. Of these, 3,326 specimens showed significant bacterial growth, giving an overall culture positivity rate of 38.0%, while 5,419 specimens were culture-negative. Among all submitted specimens, 6,123 were from female patients and 2,622 were from male patients. Because culture positivity was not stratified by sex, these figures represent the sex distribution of submitted samples only and should not be interpreted as sex-specific UTI prevalence.

Table 1. Culture Results and Sex Distribution of Submitted Urine Specimens

Variable	Category	n	%
Total urine specimens processed	—	8,745	100.0
Culture result	Culture-positive	3,326	38.0
Culture result	Culture-negative	5,419	62.0
Sex distribution of submitted specimens	Female	6,123	70.0
Sex distribution of submitted specimens	Male	2,622	30.0

Among the 3,326 culture-positive samples, *Klebsiella* spp. were isolated in 312 cases, representing 9.4% of culture-positive samples. *Proteus* spp. were isolated in 48 cases, representing 1.4% of culture-positive

samples. Together, *Klebsiella* spp. and *Proteus* spp. accounted for 360 isolates, or 10.8% of all culture-positive urine samples.

Table 2. Frequency of *Klebsiella* spp. and *Proteus* spp. Among Culture-Positive Urine Samples

Organism	Number of isolates	Percentage among culture-positive samples, N = 3,326
<i>Klebsiella</i> spp.	312	9.4
<i>Proteus</i> spp.	48	1.4
Combined <i>Klebsiella</i> spp. and <i>Proteus</i> spp. isolates	360	10.8
Other culture-positive organisms	2,966	89.2

Comparative antimicrobial susceptibility patterns showed organism-specific variation across several antibiotic classes. Among aminoglycosides, *Klebsiella* spp. showed susceptibility rates of 64% to amikacin, 65% to gentamicin, and 51% to tobramycin, while *Proteus* spp. showed susceptibility rates of 73%, 58%, and 44%, respectively. Piperacillin/tazobactam showed higher reported susceptibility among *Proteus* spp. than *Klebsiella* spp., with susceptibility rates of 79% and 46%, respectively.

Carbapenems showed the highest reported activity against *Proteus* spp., with 100% susceptibility to both imipenem and meropenem. In comparison, *Klebsiella* spp. showed susceptibility rates of 73% to imipenem and 72% to meropenem. Ceftazidime-avibactam also showed higher susceptibility among *Proteus* spp. than *Klebsiella* spp., with rates of 81% and 64%, respectively. Among cephalosporins, *Proteus* spp. showed higher susceptibility to cefepime and ceftriaxone than *Klebsiella* spp. However, ceftriaxone susceptibility of 0% in *Klebsiella* spp. and cefotaxime susceptibility of 1% in *Proteus* spp. should be verified against raw laboratory records because these values appear unusual and may substantially affect interpretation. Fluoroquinolone susceptibility was reduced in both organisms, with ciprofloxacin and levofloxacin susceptibility of 42% among *Klebsiella* spp. and 46% among *Proteus* spp.

Table 3. Comparative Antimicrobial Susceptibility Patterns of *Klebsiella* spp. and *Proteus* spp. Urine Isolates

Antibiotic	<i>Klebsiella</i> spp. susceptible, %	<i>Proteus</i> spp. susceptible, %
Amikacin	64	73
Gentamicin	65	58
Tobramycin	51	44
Amoxicillin/clavulanic acid	23	19
Ampicillin	1	11
Piperacillin/tazobactam	46	79
Co-trimoxazole	43	29
Imipenem	73	100
Meropenem	72	100
Cefepime	38	67
Cefixime	31	40
Cefotaxime	32	1*
Ceftazidime-avibactam	64	81
Ceftriaxone	0*	54
Cefuroxime	NA	NA
Ciprofloxacin	42	46
Levofloxacin	42	46
Fosfomycin	37	13
Nitrofurantoin	28	3
Doxycycline	42	3
Minocycline	3†	NA
Tigecycline	3†	NA
Colistin	22†	NA

*The ceftriaxone and cefotaxime findings were retained as reported in the laboratory dataset and should be interpreted in the context of local testing practices and organism-specific susceptibility reporting.

†Minocycline, tigecycline, and colistin were included as reported in the laboratory susceptibility panel; their clinical interpretation for urinary isolates should be guided by institutional protocols and applicable antimicrobial susceptibility testing standards.

The highest reported susceptibility among *Klebsiella* spp. was observed for imipenem, meropenem, gentamicin, ceftazidime-avibactam, and amikacin. Among *Proteus* spp., the highest susceptibility was observed for imipenem, meropenem, ceftazidime-avibactam, piperacillin/tazobactam, and amikacin.

Table 4. Antibiotics Showing Highest Reported Susceptibility by Organism


Organism	Antibiotic	Reported susceptibility, %
<i>Klebsiella</i> spp.	Imipenem	73
<i>Klebsiella</i> spp.	Meropenem	72
<i>Klebsiella</i> spp.	Gentamicin	65
<i>Klebsiella</i> spp.	Ceftazidime-avibactam	64
<i>Klebsiella</i> spp.	Amikacin	64
<i>Proteus</i> spp.	Imipenem	100
<i>Proteus</i> spp.	Meropenem	100
<i>Proteus</i> spp.	Ceftazidime-avibactam	81
<i>Proteus</i> spp.	Piperacillin/tazobactam	79
<i>Proteus</i> spp.	Amikacin	73

The lowest reported susceptibility among *Klebsiella* spp. was observed for ceftriaxone, ampicillin, minocycline, tigecycline, and amoxicillin/clavulanic acid. Among *Proteus* spp., the lowest reported susceptibility was observed for cefotaxime, nitrofurantoin, doxycycline, ampicillin, and fosfomycin. The low nitrofurantoin susceptibility in *Proteus* spp. should be interpreted cautiously because *Proteus* spp. are generally considered poor targets for nitrofurantoin therapy.

Table 5. Antibiotics Showing Lowest Reported Susceptibility by Organism

Organism	Antibiotic	Reported susceptibility, %
<i>Klebsiella</i> spp.	Ceftriaxone*	0
<i>Klebsiella</i> spp.	Ampicillin	1
<i>Klebsiella</i> spp.	Minocycline†	3
<i>Klebsiella</i> spp.	Tigecycline†	3
<i>Klebsiella</i> spp.	Amoxicillin/clavulanic acid	23
<i>Proteus</i> spp.	Cefotaxime*	1
<i>Proteus</i> spp.	Nitrofurantoin	3
<i>Proteus</i> spp.	Doxycycline	3
<i>Proteus</i> spp.	Ampicillin	11
<i>Proteus</i> spp.	Fosfomycin	13

*Reported according to the available laboratory susceptibility dataset. †Included as part of the laboratory susceptibility panel; clinical interpretation for urinary isolates should follow institutional protocols and applicable susceptibility-testing standards.



A total of 8,745 urine specimens were processed. Of these, 3,326 (38.0%) were culture-positive and 5,419 (62.0%) were culture-negative.

Figure 1. Distribution of Urine Culture Results Among Submitted Specimens

Figure 1 shows that, among 8,745 urine specimens processed during the study period, 3,326 (38.0%) yielded significant bacterial growth, while 5,419 (62.0%) were culture-negative. This indicates that

slightly more than one-third of submitted urine samples were culture-positive in this tertiary care laboratory setting. The finding supports the relevance of routine urine culture for identifying clinically significant bacterial growth and generating local antimicrobial susceptibility data. However, because the figure presents overall culture results only, it does not identify organism-specific burden, patient-level risk factors, or sex-specific culture positivity.




Figure 2. Comparative Antimicrobial Susceptibility Patterns of *Klebsiella* spp. and *Proteus* spp. Urine Isolates

Figure 2 demonstrates clear organism-specific differences in antimicrobial susceptibility between *Klebsiella* spp. and *Proteus* spp. urine isolates. *Proteus* spp. showed the highest susceptibility to carbapenems, with 100% susceptibility to both imipenem and meropenem, compared with 73% and 72%, respectively, among *Klebsiella* spp. Ceftazidime-avibactam and piperacillin/tazobactam also showed higher activity against *Proteus* spp. than *Klebsiella* spp., whereas fluoroquinolone susceptibility was reduced in both organisms, with ciprofloxacin and levofloxacin susceptibility of 42% in *Klebsiella* spp. and 46% in *Proteus* spp. Overall, the figure supports the study's main finding that *Klebsiella* spp. exhibited a less favorable susceptibility profile than *Proteus* spp., reinforcing the need for organism-specific susceptibility testing and local antibiogram-guided empirical therapy.

DISCUSSION

The present study compared the antimicrobial susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. isolated from urine cultures processed in a tertiary care hospital laboratory in Lahore, Pakistan. Among 8,745 urine specimens processed during the study period, 3,326 (38.0%) showed significant bacterial growth. Of the culture-positive samples, *Klebsiella* spp. accounted for 312 (9.4%) isolates and *Proteus* spp. for 48 (1.4%) isolates. The principal finding of the study was that *Proteus* spp. demonstrated a comparatively more favorable susceptibility profile than *Klebsiella* spp., particularly against carbapenems and selected beta-lactam/beta-lactamase inhibitor combinations. In contrast, *Klebsiella* spp. showed reduced susceptibility across several commonly used antimicrobial classes, highlighting its importance as a resistant uropathogen in this hospital setting.

The overall culture positivity rate observed in this study indicates a substantial diagnostic yield among submitted urine specimens. However, these findings should be interpreted as laboratory culture positivity rather than population-level prevalence because the study was based on specimens submitted for microbiological testing rather than a defined community cohort. Although a greater proportion of submitted specimens originated from female patients, sex-specific infection rates could not be determined because culture positivity was not stratified according to sex (9,10).

Klebsiella spp. demonstrated only moderate susceptibility to carbapenems, with susceptibility rates of 73% for imipenem and 72% for meropenem. These findings are clinically important because carbapenems are commonly reserved for severe infections caused by resistant Gram-negative organisms. Reduced susceptibility among *Klebsiella* isolates may reflect increasing antimicrobial selection pressure in tertiary care settings and emphasizes the importance of antimicrobial stewardship and susceptibility-guided therapy (11-13). In contrast, *Proteus* spp. demonstrated complete susceptibility to both imipenem and meropenem in the present dataset. Although this finding suggests preserved in-vitro activity of carbapenems against *Proteus* isolates in this setting, interpretation should be cautious because the number of *Proteus* isolates was relatively small compared with *Klebsiella* isolates. The findings related to beta-lactam and beta-lactam/beta-lactamase inhibitor agents further demonstrated organism-specific variability. *Proteus* spp. showed higher susceptibility to piperacillin/tazobactam and ceftazidime-avibactam than *Klebsiella* spp., suggesting comparatively better retained activity of these agents against *Proteus* isolates in the current study setting. These findings support the continued usefulness of selected inhibitor-protected beta-lactam agents when guided by susceptibility testing.

Reduced susceptibility to cephalosporins was observed in both organisms. *Klebsiella* spp. demonstrated low susceptibility to cefepime and cefotaxime, while ceftriaxone susceptibility was reported as 0% in the available laboratory data. *Proteus* spp. showed higher susceptibility to cefepime and ceftriaxone but markedly low susceptibility to cefotaxime. Because cefotaxime and ceftriaxone are both third-generation cephalosporins, the observed discrepancy should be interpreted cautiously and verified against original laboratory antimicrobial susceptibility records before definitive conclusions are drawn. Nevertheless, the overall findings suggest reduced reliability of several conventional cephalosporins for empirical treatment of urinary tract infections caused by these organisms in the present setting.

Fluoroquinolone susceptibility was reduced in both organisms, with susceptibility rates of 42% among *Klebsiella* spp. and 46% among *Proteus* spp. for both ciprofloxacin and levofloxacin. This finding is clinically important because fluoroquinolones remain commonly prescribed oral agents for urinary tract infections. The reduced susceptibility observed in the present study suggests that empirical fluoroquinolone therapy may be unreliable in this hospital setting unless supported by current local antibiogram data or isolate-specific susceptibility testing.

Lower susceptibility was also observed for several commonly used antimicrobial agents. *Klebsiella* spp. demonstrated very low susceptibility to ampicillin and limited susceptibility to amoxicillin/clavulanic acid, nitrofurantoin, and fosfomycin. *Proteus* spp. also demonstrated low susceptibility to ampicillin, fosfomycin, nitrofurantoin, and doxycycline. The low reported susceptibility of *Proteus* spp. to nitrofurantoin should be interpreted cautiously because *Proteus* species are generally considered intrinsically less susceptible to nitrofurantoin and are not ideal targets for nitrofurantoin therapy (14,15).

The present findings are broadly consistent with previous studies reporting increasing antimicrobial resistance among Gram-negative uropathogens. Studies by Caneiras et al., Bobbadi et al., Vaez et al., and Cohen-Nahum et al. similarly reported variable susceptibility profiles among *Klebsiella* and *Proteus* isolates, particularly with reduced activity of fluoroquinolones and cephalosporins (15-18). However, direct comparisons should be interpreted cautiously because antimicrobial panels, study populations, laboratory methodologies, and local resistance patterns differ between institutions and regions.

From a clinical perspective, the present study highlights the importance of routine culture and antimicrobial susceptibility testing for urinary tract infections in tertiary care settings where resistant Gram-negative organisms are frequently encountered. The findings support regular updating of institutional antibiograms and careful selection of empirical therapy based on local susceptibility trends rather than generalized assumptions regarding organism susceptibility.

This study has several limitations. First, it was conducted in a single tertiary care hospital laboratory, which may limit generalizability to other healthcare settings or geographic regions. Second, the sample size of *Proteus* spp. isolates was relatively small compared with *Klebsiella* spp. isolates, which may affect comparative interpretation. Third, patient-level clinical data, including prior antibiotic exposure, inpatient or outpatient status, catheterization history, and comorbidities, were not available for analysis. Finally, molecular characterization of resistance mechanisms such as ESBL or carbapenemase production was not performed. Despite these limitations, the study provides useful local laboratory evidence regarding the comparative antimicrobial susceptibility patterns of *Klebsiella* spp. and *Proteus* spp. isolated from urine cultures in a tertiary care hospital setting. The findings reinforce the practical importance of local microbiology surveillance, organism-specific antibiogram reporting, and antimicrobial stewardship programs in guiding empirical therapy and preserving the effectiveness of remaining therapeutic options.

CONCLUSION

This laboratory-based observational study demonstrated distinct antimicrobial susceptibility patterns among *Klebsiella* spp. and *Proteus* spp. isolated from urine cultures in a tertiary care hospital setting in Lahore, Pakistan. *Proteus* spp. retained high susceptibility to carbapenems, whereas *Klebsiella* spp. showed comparatively reduced susceptibility across several commonly used antimicrobial classes. Reduced susceptibility to fluoroquinolones and multiple beta-lactam agents in both organisms highlights the growing challenge of antimicrobial resistance in urinary tract infections. These findings support the routine use of culture-based antimicrobial susceptibility testing, regular updating of local antibiograms, and susceptibility-guided therapy to improve empirical treatment decisions and strengthen antimicrobial stewardship practices.

RECOMMENDATIONS AND LIMITATIONS

Empirical therapy for urinary tract infections should be supported by regularly updated local antibiogram data and culture-based susceptibility testing wherever feasible. Rational antimicrobial prescribing and strengthened antimicrobial stewardship programs are important to reduce unnecessary use of broad-spectrum antibiotics and preserve the effectiveness of higher-tier agents such as carbapenems and newer beta-lactam/beta-lactamase inhibitor combinations. Continued microbiological surveillance and periodic reassessment of local resistance trends are also recommended.

The present study was limited by its single-center design and unequal isolate distribution between *Klebsiella* spp. and *Proteus* spp. The study also lacked patient-level clinical information, including prior antibiotic exposure, hospitalization status, catheterization history, and associated comorbidities. In addition, molecular characterization of resistance mechanisms such as ESBL or carbapenemase production was not performed. Some reported cephalosporin susceptibility findings should also be verified against original laboratory antimicrobial susceptibility records before definitive interpretation.

REFERENCES

1. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. *PLoS One*. 2017;12(12):e0189621.
2. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob Health*. 2015;109(7):309-18.

3. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. *J Glob Infect Dis.* 2019;11(1):36-42.
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta: US Department of Health and Human Services; 2019.
5. Tang KWK, Millar BC, Moore JE. Antimicrobial resistance. *Br J Biomed Sci.* 2023;80:11387.
6. Sarathbabu R, Ramani T, Rao KB, Panda S. Antibiotic susceptibility pattern of *Klebsiella pneumoniae* isolated from sputum, urine and pus samples. *IOSR J Pharm Biol Sci.* 2012;1(2):4-9.
7. Farajnia S, Alikhani MY, Ghotaslou R, Naghili B, Nakhband A. Causative agents and antimicrobial susceptibilities of urinary tract infections in northwest Iran. *Int J Infect Dis.* 2009;13(2):140-4.
8. Ohieku JD, Magaji RA. Urinary tract infections caused by *Pseudomonas*, *Klebsiella* and *Proteus* species: a 2005-2009 survey of trends in their infectivities and susceptibilities to selected fluoroquinolones in a tertiary hospital in Nigeria. *World J Pharm Res.* 2013;2(5):1238-53.
9. Mobley HL, Belas R. Swarming and pathogenicity of *Proteus mirabilis* in the urinary tract. *Trends Microbiol.* 1995;3(7):280-4.
10. Harrison LH, Cass AS, Bullock BC, Cox CE. Experimental pyelonephritis in dogs. I. Confirmation by antibody response. *J Urol.* 1973;109(2):163-6.
11. Warren JW. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. *J Infect Dis.* 1982;146(6):719-23.
12. Broomfield RJ, Morgan SD, Khan A, Stickler DJ. Crystalline bacterial biofilm formation on urinary catheters by urease-producing urinary tract pathogens: a simple method of control. *J Med Microbiol.* 2009;58(Pt 10):1367-75.
13. Gul A. Microorganisms and antibiotic susceptibilities isolated from urine cultures. *Arch Ital Urol Androl.* 2020.
14. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. *JAMA.* 2016;316(11):1193-204.
15. Caneiras C, Lito L, Melo-Cristino J, Duarte A. Community- and hospital-acquired *Klebsiella pneumoniae* urinary tract infections in Portugal: virulence and antibiotic resistance. *Microorganisms.* 2019;7(5):138.
16. Bobbadi S, Chinnam BK, Reddy PN, Kandhan S. Analysis of antibiotic resistance and virulence patterns in *Klebsiella pneumoniae* isolated from human urinary tract infections in India. *Lett Appl Microbiol.* 2021;73(5):590-8.
17. Vaez H, Kalarestaghi H, Sahebkar A, Khademi F. Prevalence of antibiotic resistance of *Proteus* species in urinary tract infections in Iran: a systematic review and meta-analysis. *Gene Rep.* 2022;27:101632.
18. Cohen-Nahum K, Saidel-Odes L, Riesenberk K, Schlaeffer F, Borer A. Urinary tract infections caused by multidrug-resistant *Proteus mirabilis*: risk factors and clinical outcomes. *Infection.* 2010;38():41-6.